US Patent Issued to Alnylam Pharmaceuticals on Jan. 27 for "Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof" (Massachusetts Inventors)

ALEXANDRIA, Va., Jan. 28 -- United States Patent no. 12,534,731, issued on Jan. 27, was assigned to Alnylam Pharmaceuticals Inc. (Cambridge, Mass.).

"Alpha-2A adrenergic receptor (ADRA2A) iRNA agent compositions and methods of use thereof" was invented by Bret L. Bostwick (Cambridge, Mass.), James D. Mcininch (Burlington, Mass.) and Adam Castoreno (Framingham, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting an alpha-2A adrenergic receptor (ADRA2A) gene, as well as methods of inhibiting expression of an ADRA2A gene and methods of treating subjects having an ADRA2A-associated disease or disorder, e.g., a ...